Monitoring using continuous glucose monitoring system (CGM) for prediction of venous thrombosis after free flap breast reconstructions.

Monitoring using continuous glucose monitoring system (CGM) for prediction of venous thrombosis after free flap breast reconstructions, single center, investigated initiated study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0010824

Enrollment

100

Registered

2025-07-29

Start date

2024-10-15

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Patients who underwent abdominal flap-based breast reconstruction are included. Each patient received two CGM sensors intraoperatively (Guardian 4, Medtronic, USA), on the flap skin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who undergoing immediate or delayed breast reconstruction using abdominal free flap following nipple-sparing or skin-sparing mastectomy.

Exclusion criteria

Exclusion criteria: 1. Patients younger than 19 years old. 2. Chronic degenerative disease, severe heart failure 3. Bleeding disease ( intracranial, gasgtrointestinal, hematochesia) 4. Patients with pregnancy, possible pregnancy 5. Diabetes, uncontrollable 6. Coagulative disorder, hematologic disease.

Design outcomes

Primary

Measure	Time frame
Number of Low glucose alarm (<60mg/dL)	—

Secondary

Measure	Time frame
Sensitivity, specificity using criteria of 50mg/dl , 60mg/dl, and 70 mg/dl for prediction of venous thrombosis of the flap	—

Countries

Korea, Republic of

Contacts

Public ContactKYONGJE WOO

Samsung Medical Center

economywoo@gmail.com+82-2-3410-3904

Outcome results